IRVINE, Calif., Aug. 7, 2006 (PRIMEZONE) -- "As the headline-grabbing battle regarding embryonic stem cell research rages, adult stem cell sources continue to provide an ever-broadening array of life-improving possibilities," stated SmallCap Sentinel analyst D.R. Clark. "Researchers are using the far less controversial adult stem cells to attack enormous medical problems and are confident enough in their successes thus far to seek the protection of U.S. Patents."
"Along these lines, Medistem Laboratories, Inc. (OTCBB:MDSM) has filed a patent application with the United States Patent and Trademark Office for a potential stem cell therapy for erectile dysfunction to complement a previous patent application for stem cell treatment for back problems," Clark added. "We're seeing continued expansion of ideas using adult stem cells for a wide variety of medical purposes."
The informational report "Looking at the Political Impact on Stem Cell Research" is available at www.SmallCapSentinel.com and will address issues affecting stem cell companies including Genentech, Inc. (NYSE:DNA), Sepracor Inc. (Nasdaq:SEPR), and Celgene Corporation (Nasdaq:CELG) and Medistem.
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The Company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the Company believes to be non-controversial sources of stem cells. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients.
For more information on Medistem please visit: http://www.trilogy-capital.com/tcp/medistem/.
To read or download Medistem's Investor Fact Sheet, please visit: http://www.trilogy-capital.com/tcp/medistem/factsheet.html.
Individuals may also register to receive future informational reports regarding this subject at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Medistem for preparation and distribution of this report and other advertising services. An editor of SmallCap Sentinel currently holds a position in STEM. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.